Project Grant R01AI201855
Award Date 8/10/26
Completion Date 7/31/31
Dollars Obligated $674K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $182,196 on June 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antibody-driven bioconjugation methods that chemically modify primary immune cells and disease-associated proteins to redirect cytotoxicity toward diseased cells as an alternative to genetic engineering approaches. The award funds synthesis and characterization...
- The National Institute of Allergy and Infectious Diseases awarded The University Corporation $147,500 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a multi-scale study of antimicrobial peptide action in non-standard bacterial growth states. The project addresses how antimicrobial peptides (AMPs)—immune-derived molecules that kill bacteria by disrupting membranes and modulate host immune responses—perform under physiologically relevant...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded the Regents of the University of California, doing business as University of California, Berkeley, $240,750 on August 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop computational and experimental methods to track plasmid dynamics in the human gut microbiome in response to...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $171,296 on February 3, 2027, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop methods for augmenting bacteriophages to improve their efficacy against Pseudomonas aeruginosa infections. The funded research will develop methods to express soluble effectors during bacteriophage infection that degrade Pseudomonas' protective biofilm upon...
- The National Institute of Allergy and Infectious Diseases awarded the University of California Irvine $196,250 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop coordinate covalent protease inhibitors using a bioinorganic approach. The recipient will synthesize and characterize rhenium(I) transition metal complexes to inhibit the SARS-CoV-2 main protease (3CLpro) through a hit-to-lead, proof-of-concept effort. Specific Aim 1 will employ a...
- The National Institute of Allergy and Infectious Diseases awarded $185,644 to the University of California, Berkeley on August 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a high-throughput pipeline for discovering novel antimicrobial compounds produced by actinomycetes with activity against Mycobacterium tuberculosis. The research pipeline uses 3D-printed assay plates to grow rare actinomycetes in interaction pairs, a condition that triggers...
- The National Institute of Allergy and Infectious Diseases awarded the J. David Gladstone Institutes $2,047,959 on May 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish the Phaige Therapy Center, developing AI-guided molecular tools and preclinical assays for rapid bacteriophage design and testing against multidrug-resistant ESKAPE pathogens with a focus on Klebsiella pneumoniae. The award funds two primary research projects. Project 1 develops...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, San Diego $240,000 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop new drug leads targeting F1F0 ATP synthase inhibitors for treatment of primary amoebic meningoencephalitis caused by Naegleria fowleri. The research identified two pure compounds derived from marine microbial metabolites that exhibit nanomolar potency against multiple N. fowleri...
- The National Institute of Allergy and Infectious Diseases awarded The Broad Institute, Inc. $480,650 on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a genome-wide association study identifying genetic determinants of carbapenem resistance in Klebsiella pneumoniae. The project addresses knowledge gaps in understanding resistance mechanisms in carbapenem-resistant K. pneumoniae strains. The recipient will perform a reference-free GWAS using...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, San Diego $240,000 on July 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Assistance Listing Project Grant R21AI202438). The research targets cryptosporidiosis, a severe diarrheal disease caused by the parasite Cryptosporidium parvum, by developing novel therapeutics that exploit the parasite's proteasome as a druggable target. The first project aim produces and...